{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:33:44Z","timestamp":1778589224314,"version":"3.51.4"},"reference-count":30,"publisher":"American Veterinary Medical Association (AVMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["javma"],"published-print":{"date-parts":[[2009,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:p><jats:bold>Objective<\/jats:bold>\u2014To assess tolerability and short-term efficacy of oral administration of pregabalin as an adjunct to phenobarbital, potassium bromide, or a combination of phenobarbital and potassium bromide for treatment of dogs with poorly controlled suspected idiopathic epilepsy.<\/jats:p>\n<jats:p><jats:bold>Design<\/jats:bold>\u2014Open-label, noncomparative clinical trial.<\/jats:p>\n<jats:p><jats:bold>Animals<\/jats:bold>\u201411 client-owned dogs suspected of having idiopathic epilepsy that was inadequately controlled with phenobarbital, potassium bromide, or a combination of these 2 drugs.<\/jats:p>\n<jats:p><jats:bold>Procedures<\/jats:bold>\u2014Dogs were treated with pregabalin (3 to 4 mg\/kg [1.4 to 1.8 mg\/lb], PO, q 8 h) for 3 months. Number of generalized seizures in the 3 months before and after initiation of pregabalin treatment was recorded. Number of responders (\u2265 50% reduction in seizure frequency) was recorded, and seizure frequency before and after initiation of pregabalin treatment was compared by use of a nonparametric Wilcoxon signed rank test.<\/jats:p>\n<jats:p><jats:bold>Results<\/jats:bold>\u2014Seizures were significantly reduced (mean, 57%; median, 50%) after pregabalin administration in the 9 dogs that completed the study; 7 were considered responders with mean and median seizure reductions of 64% and 58%, respectively. Adverse effects for pregabalin were reported in 10 dogs. Mean and median plasma pregabalin concentrations for all dogs were 6.4 and 7.3 \u03bcg\/mL, respectively.<\/jats:p>\n<jats:p><jats:bold>Conclusions and Clinical Relevance<\/jats:bold>\u2014Pregabalin may hold promise as a safe and effective adjunct anticonvulsant drug for epileptic dogs poorly controlled with the standard drugs phenobarbital or potassium bromide. Adverse effects of pregabalin appeared to be mild. Additional studies with larger numbers of dogs and longer follow-up intervals are warranted.<\/jats:p>","DOI":"10.2460\/javma.235.12.1442","type":"journal-article","created":{"date-parts":[[2009,12,15]],"date-time":"2009-12-15T14:02:54Z","timestamp":1260885774000},"page":"1442-1449","source":"Crossref","is-referenced-by-count":41,"title":["Pregabalin as an adjunct to phenobarbital, potassium bromide, or a combination of phenobarbital and potassium bromide for treatment of dogs with suspected idiopathic epilepsy"],"prefix":"10.2460","volume":"235","author":[{"given":"Curtis W.","family":"Dewey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Cerda-Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan M.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britton L.","family":"Badgley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie M.","family":"Ducot\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gena M.","family":"Silver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jocelyn J.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca A.","family":"Packer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A.","family":"Lavely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1272","reference":[{"key":"ref1","series-title":"A practical guide to canine and feline neurology","first-page":"237","article-title":"Seizures and narcolepsy","author":"Thomas","year":"2008"},{"key":"ref2","series-title":"Vet Clin North Am Small Anim Pract","first-page":"411","article-title":"Anticonvulsant therapy in small animals","volume":"28","author":"Boothe","year":"1998"},{"key":"ref3","series-title":"J Vet Intern Med","first-page":"318","article-title":"Bromide therapy in refractory canine idiopathic epilepsy","volume":"7","author":"Podell","year":"1993"},{"key":"ref4","series-title":"J Vet Intern Med","first-page":"754","article-title":"Premature death, risk factors, and life patterns in dogs with epilepsy","volume":"21","author":"Berendt","year":"2007"},{"key":"ref5","series-title":"Vet Clin North Am Small Anim Pract","first-page":"1107","article-title":"Anticonvulsant therapy in dogs and cats","volume":"36","author":"Dewey","year":"2006"},{"key":"ref6","series-title":"Expert Opin Investig Drugs","first-page":"637","article-title":"New antiepileptic drugs that are second generation to existing antiepileptic drugs","volume":"15","author":"Bialer","year":"2006"},{"key":"ref7","series-title":"Curr Opin Pharmacol","first-page":"108","article-title":"The mechanisms of action of gabapentin and pregabalin","volume":"6","author":"Sills","year":"2006"},{"key":"ref8","series-title":"Am J Health Syst Pharm","first-page":"1475","article-title":"Pregabalin: an antiepileptic agent useful for neuropathic pain","volume":"64","author":"Blommel","year":"2007"},{"key":"ref9","series-title":"Epilepsy Res","first-page":"137","article-title":"Pharmacology and mechanism of action of pregabalin: the calcium channel \u03b12-\u03b4 (alpha2-delta) subunit as a target for antiepileptic drug discovery","volume":"73","author":"Taylor","year":"2007"},{"key":"ref10","series-title":"Epilepsy Res","first-page":"189","article-title":"Activity profile of pregabalin in rodent models of epilepsy and ataxia","volume":"68","author":"Vartanian","year":"2006"},{"issue":"suppl 6","key":"ref11","series-title":"Epilepsia","first-page":"13","article-title":"Pregabalin pharmacology and its relevance to clinical practice","volume":"45","author":"Ben-Menachem","year":"2004"},{"issue":"suppl 6","key":"ref12","series-title":"Epilepsia","first-page":"19","article-title":"Pregabalin as adjunctive therapy for partial seizures","volume":"45","author":"Brodie","year":"2004"},{"issue":"suppl 4","key":"ref13","series-title":"Eur J Neurol","first-page":"12","article-title":"Defining success in clinical trials-profiling pregabalin, the newest AED","volume":"12","author":"Ryvlin","year":"2005"},{"key":"ref14","series-title":"Vet Rec","first-page":"881","article-title":"Treatment with gabapentin of 11 dogs with refractory idiopathic epilepsy","volume":"159","author":"Platt","year":"2006"},{"key":"ref15","series-title":"Aust Vet J","first-page":"602","article-title":"Improving seizure control in dogs with refractory epilepsy using gabapentin as an adjunctive agent","volume":"83","author":"Govendir","year":"2005"},{"key":"ref16","series-title":"Vet Anaesth Analg","first-page":"574","article-title":"Pharmacokinetics of single-dose oral pregabalin administration in normal dogs","volume":"36","author":"Salazar","year":"2009"},{"key":"ref17","series-title":"Ther Drug Monit","first-page":"451","article-title":"Analysis of pregabalin at therapeutic concentrations in human plasma\/serum by reversed-phase HPLC","volume":"27","author":"Berry","year":"2005"},{"key":"ref18","series-title":"J Am Vet Med Assoc","first-page":"1449","article-title":"Therapeutic serum drug concentrations in epileptic dogs treated with potassium bromide alone or in combination with other anticonvulsants: 122 cases (1992\u20131996)","volume":"213","author":"Trepanier","year":"1998"},{"key":"ref19","series-title":"J Pharm Sci","first-page":"249","article-title":"Fluorescamine use in high-performance liquid chromatographic determination of aminocaproic acid in serum","volume":"68","author":"Farid","year":"1979"},{"key":"ref20","series-title":"J Am Anim Hosp Assoc","first-page":"285","article-title":"Zonisamide therapy for refractory idiopathic epilepsy in dogs","volume":"40","author":"Dewey","year":"2004"},{"key":"ref21","series-title":"J Small Anim Pract","first-page":"134","article-title":"Prospective study of zonisamide therapy for refractory idiopathic epilepsy in dogs","volume":"48","author":"Von Klopmann","year":"2007"},{"key":"ref22","series-title":"Vet J","first-page":"310","article-title":"The efficacy and tolerability of levetiracetam in pharmacoresistant epileptic dogs","volume":"176","author":"Volk","year":"2008"},{"key":"ref23","series-title":"Proceedings","first-page":"338","article-title":"The placebo effect in epilepsy studies","author":"Munana","year":"2008"},{"key":"ref24","series-title":"J Small Anim Pract","first-page":"574","article-title":"Idiopathic epilepsy in dogs: owners' perspectives on management with phenobarbitone and\/or potassium bromide","volume":"47","author":"Chang","year":"2006"},{"key":"ref25","series-title":"Drug Metab Dispos","first-page":"441","article-title":"Disposition of gabapentin (Neurontin) in mice, rats, dogs, and monkeys","volume":"23","author":"Radulovic","year":"1995"},{"key":"ref26","series-title":"Drug Res","first-page":"830","article-title":"Pharmacokinetics and metabolism of gabapentin in rat, dog and man","volume":"36","author":"Vollmer","year":"1986"},{"key":"ref27","series-title":"Can Vet J","first-page":"555","article-title":"Pancreatitis associated with potassium bromide\/phenobarbital combination therapy in epileptic dogs","volume":"41","author":"Gaskill","year":"2000"},{"key":"ref28","series-title":"Vet Ther","first-page":"37","article-title":"Serum pancreatic lipase immunoreactivity concentrations in dogs treated with potassium bromide and\/or phenobarbital","volume":"9","author":"Steiner","year":"2008"},{"key":"ref29","series-title":"Epilepsia","first-page":"1926","article-title":"Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study","volume":"46","author":"Elger","year":"2005"},{"key":"ref30","series-title":"Neurology","first-page":"475","article-title":"Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy","volume":"64","author":"Beydoun","year":"2005"}],"container-title":["Journal of the American Veterinary Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/235\/12\/javma.235.12.1442.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/235\/12\/javma.235.12.1442.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/235\/12\/javma.235.12.1442.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T13:50:13Z","timestamp":1741355413000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/235\/12\/javma.235.12.1442.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,15]]},"references-count":30,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.2460\/javma.235.12.1442","relation":{},"ISSN":["0003-1488"],"issn-type":[{"value":"0003-1488","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12,15]]}}}